Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 665

Abalos attracts series A attention

Boehringer Ingelheim Venture Fund co-led a $13.3m round for the immuno-oncoclogy startup, which was spun out of University of Duisburg-Essen’s and University of Düsseldorf.

Oct 16, 2019

Cyteir secures series B funding

The cancer therapy developer boosted a series B round led by Novo and backed by Celgene to $75.2m, with both corporates contributing to the latest tranche.

Oct 16, 2019

Legend feeds series B funding to Gambol

Legend Capital and Industrial Bank have supplied $70.5m in series B funding for Gambol Pet Group, a pet food manufacturer with operations in Asia, the US and Europe.

Oct 16, 2019

CleverTap wraps up $35m series C round

Returning investors Sequoia India and Tiger Global Management co-led a $35m round that valued Recruit-backed marketing software provider CleverTap at $385m.

Oct 16, 2019

Cyteir takes series B to $75.2m

Jackson Laboratory cancer drug spinout Cyteir Therapeutics extended its series B round thanks to investors including Osage University Partners and Novo Holdings.

Oct 16, 2019

Healx examines $56m series B

Atomico has led $56m series B round for Cambridge-allied rare disease therapy developer Healx, which also welcomed Intel Capital as a new shareholder.

Oct 16, 2019

Sequis Life books $33m appointment with Alodokter

Sequis Life led a series C round for online healthcare and insurance portal Alodokter that included Philips and existing investor SoftBank Ventures Asia.

Oct 16, 2019

Legend Capital stirs Mathpresso to series B

The SoftBank, Samsung and Megastudy-backed maths tutoring app developer secured $14.5m in a round led by Legend Capital.

Oct 16, 2019

Provivi reaps $85m in series C round

BASF Venture Capital formed part of a consortium co-led by Pontifax Agtech and Temasek that supplied $85m in funding for pesticide developer Provivi.

Oct 15, 2019

Ansun gets its hands on $80m

Lilly Asia Ventures returned for the respiratory disease drug developer's series B round, having co-led its $85m series A last year.

Oct 15, 2019
© 2026 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here